6635EGP
- Active ingredient
- beractant
- Form
- vial
- Manufacturer
- abbvie ltd.
- Route
- injection
Uses
Used for prevention and treatment of respiratory distress syndrome in premature infants.
Do not use if
No specific contraindications are established in the labeling.
Side effects
Common adverse effects include transient bradycardia, oxygen desaturation, and airway obstruction during administration.
Warnings
Should only be administered in highly supervised neonatal intensive care settings by experienced clinicians.
How it works
Pulmonary surfactant replacement therapy that reduces alveolar surface tension and improves lung function.
Storage
Store according to manufacturer recommendations and maintain cold-chain requirements.